freedom has been researched along with dacarbazine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Gui, L; He, X; Liu, P; Qin, Y; Shi, Y; Tao, Y; Yang, J; Yang, S; Zhang, C; Zhou, L; Zhou, S; Zhou, Y | 1 |
1 other study(ies) available for freedom and dacarbazine
| Article | Year |
|---|---|
A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Freedom; Hodgkin Disease; Humans; Lymphocytes; Neoplasm Staging; Prognosis; Vinblastine | 2022 |